Polypharmacy problems in geriatric practice of Kyrgyz Republic
https://doi.org/10.37489/2588-0519-2022-3-52-61
Abstract
World statistics shows increasing numbers of aging population and increasing number of patients with multiple comorbidities, i. e. polymorbidity, which today is an urgent problem of modern clinical geriatric practice. During clinical examination of elderly and senile patients, at least 4-5 diseases and manifestations of pathological processes are diagnosed on the average. Because of this many medicines are prescribed to elderly patients at the same time, unfortunately, often unreasonably, which becomes a widespread phenomenon and is called polypharmacy. Polypharmacy is associated with an increased risk of adverse reactions that can lead to hospitalization or even death, as well as a significant increase in health care costs.
In this regard, an analysis of medication prescribing in elderly inpatients with cardiovascular disease using the Medication Rationality Index (MAI) was conducted. As a result, it was found that professionals who provide care to patients are not sufficiently aware of the peculiarities of the use of drugs in elderly patients and in our health care sector there are no regulatory documents on the care of elderly patients.
About the Authors
A. T. Sharaeva
State Educational Institution of Higher Professional Education Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B. N. Yeltsin
Kyrgyzstan
Kyrgyzstan
Sharaeva Ainura T., Cand. Sci. Med., Assistant Professor
Bishkek
A. A. Zurdinova
State Educational Institution of Higher Professional Education Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B. N. Yeltsin
Kyrgyzstan
Kyrgyzstan
Zurdinova Aida A., Dr. Sci. (Med.), Assistant Professor
Bishkek
References
1. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019, Online Edition. POP/DB/WPP/Rev.2019/POP/F08-1.
2. Pozhilye lyudi v Kyrgyzskoj Respublike. Otchet statisticheskogo issledovaniya, Bishkek, 2017 g. (In Russ). Доступен по ссылке: http://www.stat.kg/ru/publications/pozhilye-lyudi-v-kyrgyzskoj-respublike/. Ссылка активна на 27.09.2022.
3. World Health Organization (2008). The World Health Report 2008. Primary Health Care — Now More than Ever. New York: The World Health Organization.
4. National Guideline Centre. (2016). Multimorbidity: Assessment, Prioritisation and Management of Care for People with Commonly Occurring Multimorbidity. NICE Guideline, London, UK. Available at: nice.org.uk/ guidance/ng56.
5. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74. doi: 10.1186/s12916-015-0322-7
6. Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health Outcomes Associated with Polypharmacy in Community-Dwelling Older Adults: a Systematic Review. J Am Geriatr Soc. 2014;62(12):2261–72. doi: 10.1111/jgs.13153
7. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65. doi: 10.1517/14740338.2013.827660
8. Payne RA, Avery AJ. Polypharmacy: One of the Greatest Prescribing Challenges in General Practice. Br J Gen Pract. 2011;61(583):83–4. doi: 10.3399/bjgp11X556146
9. Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289–98. doi: 10.2147/CLEP.S153458
10. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43. doi: 10.1016/S0140-6736(12)60240-2
11. Kardas P, Urbański F, Lichwierowicz A, Chudzyńska E, Kardas G, Czech M. Prevalence and age structure of polypharmacy in Poland: Results of the Analysis of the National Real-World Database of 38 Million Citizens. Front Pharmacol. 2021;12:655364. doi: 10.3389/fphar.2021.655364
12. Stewart D, Mair A, Wilson M, Kardas P, Lewek P, Alonso A, et al. Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opin Drug Saf. 2017;16(2):203–13. doi: 10.1080/14740338.2017.1265503
13. Midão L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213–20. doi: 10.1016/j.archger.2018.06.018
14. Pereira KG, Peres MA, Iop D, Boing AC, Boing AF, Aziz M, et al. Polypharmacy among the elderly: a population-based study. Rev Bras Epidemiol. 2017;20(2):335–44. doi: 10.1590/1980-5497201700020013
15. Quinn KJ, Shah NH. A dataset quantifying polypharmacy in the United States. Sci Data. 2017;4:170167. doi: 10.1038/sdata.2017.167
16. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310(23):2503–4. doi: 10.1001/jama.2013.281422
17. Farmer C, Fenu E, O'Flynn N, Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:i4843. doi: 10.1136/bmj.i4843
18. Kurczewska-Michalak M, Lewek P, Jankowska-Polańska B, Giardini A, Granata N, Maffoni M, Costa E, Midão L, Kardas P. Polypharmacy Management in the Older Adults: A Scoping Review of Available Interventions. Front Pharmacol. 2021;12:734045. doi: 10.3389/fphar.2021.734045
19. Rochon PA, Schmader KE, Givens J. Drug prescribing for older adults, 2021. Available at: https://www.uptodate.com/contents/drug-prescribing-for-older-adults. Accessed September 27, 2022.
20. Joseph T. Hanlon, Kenneth E. Schmader. The medication appropriateness index at 20: where it started, where it has been and where it may be going. Drugs Aging. 2013;30(11):893–900. doi: 10.1007/s40266-013-0118-4
21. May PS Lam, Bernard MY Cheung. The use of STOPP/START criteria as a screening tool for assessing the appropriateness of medications in the elderly population. Expert Rev Clin Pharmacol. 2012;5(2):187–97. doi: 10.1586/ecp.12.6
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74. Available at: https://pubmed.ncbi.nlm.nih.gov/843571/. Accessed September 27, 2022.
23. Sychyov D, Sosnovsky E, Otdelenov V. Medical appropriateness index as a method for polypharmacy control. Clin. Pharmacol. Ther. 2016;25(3):79–82. (In Russ). Доступен по ссылке: https://clinpharm-journal.ru/files/articles/indeks-ratsionalnosti-primeneniya-lekarstvennogo-sredstva-kak-metod-borby-s-polipragmaziej.pdf. Ссылка активна на 27.09.2022.
Review
For citations:
Sharaeva A.T., Zurdinova A.A. Polypharmacy problems in geriatric practice of Kyrgyz Republic. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2022;(3):52-61. (In Russ.) https://doi.org/10.37489/2588-0519-2022-3-52-61
Views:
858
Email this article 